Breaking News: Agios’ Pyrukynd-Mitapivat Proves Safe and Effective in Non-Transfusion-Dependent Thalassemia – Published in The Lancet!
Agios Announces Publication of Phase 2 Data in The Lancet Demonstrating Safety and Efficacy of PYRUKYND® Introduction Hey there, readers! Today we’re diving into some exciting news from Agios regarding the publication of Phase 2 data in The Lancet. The data showcases the safety and efficacy of PYRUKYND® in adults with non-transfusion-dependent α- or β-thalassemia….